Abstract Details

Title The Association Between Sleep Apnea Severity and ARIA in People with Alzheimer’s Patients Treated with Anti-amyloid Therapy

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P2 - Poster Session 2 (11:45 AM-12:45 PM)

Poster/Presentation
Number 12-002

Objective To explore the relationship between sleep apnea and ARIA development in patients with Alzheimer's disease (PwAD) treated with Lecanemab

Background Amyloid-related imaging abnormalities (ARIA) are a known complication of anti-amyloid therapies used in the treatment of PwAD. Various predictors of ARIA risk have been investigated: medical comorbidities, medication use, and genetic factors. Sleep disturbance metrics have not been as thoroughly explored in this context as a factor in the development of ARIA. This study aims to examine the relationship between ARIA status and sleep parameters in patients undergoing Lecanemab treatment.

Design/Methods A retrospective analysis was conducted on 26 PwAD (72.5 years ± 6.25) treated with Lecanemab who had documented ARIA status via MRI and available sleep study data, including predicted Apnea-Hypopnea Index (pAHI), REM sleep percentage, and total sleep percentage. Mann-Whitney U tests were performed in view of the small sample size to compare REM/total sleep percentage and pAHI between ARIA-positive and ARIA-negative patients.

Results

Of the 26 PwAD analyzed, 9 (34.6%) developed ARIA. Each subgroup analysis included 20 PwAD with valid ARIA status and corresponding sleep metric data. The Mann-Whitney U test demonstrated a statistically significant difference in pAHI scores between ARIA-positive and ARIA-negative patients (U = 9, p = 0.0286), indicating a higher sleep-disordered breathing severity in the ARIA-positive group. No significant differences were observed in REM sleep percentage (p = 0.243) or total sleep percentage (p = 0.682) between the groups.

Conclusions These preliminary findings suggest a potential association between increased sleep-disordered breathing severity and ARIA development in people with Alzheimer’s Disease treated with Lecanemab. While no significant differences were found for %REM or total sleep percentages, the significant Mann-Whitney U result for pAHI warrants further investigation.

Authors/Disclosures
Caitlyn Y. Kirshy PRESENTER	Miss Kirshy has nothing to disclose.
Alice M. Bubel, Research Volunteer	Miss Bubel has nothing to disclose.
Zainab Raza	Ms. Raza has nothing to disclose.
Joanna Weller (NYU Langone South Shore Neurologic Associates)	Joanna Weller has nothing to disclose.
Matthew Jo (NYU Langone)	Matthew Jo has nothing to disclose.
Cassidy Fitchett	Ms. Fitchett has nothing to disclose.
Barbara Bumstead, NP	Ms. Bumstead has nothing to disclose.
Danielle Walthers, NP	Mrs. Walthers has nothing to disclose.
Kelly Yip (NYU Grossman Long Island School of Medicine)	No disclosure on file
Anil Mattoo (NYU Grossman Long Island School of Medicine)	No disclosure on file
Hrayr P. Attarian, MD, FAAN (Northwestern University)	Dr. Attarian has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Avadel. Dr. Attarian has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Jazz. Dr. Attarian has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for IMS Legal. The institution of Dr. Attarian has received research support from AASM. Dr. Attarian has received publishing royalties from a publication relating to health care.
Myassar Zarif	Myassar Zarif has nothing to disclose.
Mark Gudesblatt, MD (South Shore Neurology Assoc. PC)	The institution of Dr. Gudesblatt has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for genentech. The institution of Dr. Gudesblatt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.

��ɫ��

��ɫ��